Inflazyme Pharmaceuticals Ltd.: Inflazyme Pharmaceuticals Ltd.: Shareholder Letter and Financial Results for the Quarter Ended September 30, 2006
15th Nov 2006, 01:48 GMT
VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced its second quarter financial results for the period ended September 30, 2006.
Inflazyme Pharmaceuticals Ltd.: Inflazyme Pharmaceuticals Ltd.: Shareholder Letter and Financial Results for the Quarter Ended September 30, 2006 related news:
- Symbollon Pharmaceuticals, Inc.: Symbollon Pharmaceuticals Announces Third Quarter 2006 Results — Market Wire - Pharmaceuticals and Biotech
- Vector Group Reports Third Quarter 2006 Financial Results — Nachrichten Ticker - www.finanzen.net
- Silverstar Holdings Announces Financial Results for Period Ending September 30, 2006 — ArriveNet : Business
- Loring Ward International Ltd.: Loring Ward Third Quarter Results Conference Call — Market Wire - Financial Services
- Diaz Resources Ltd.: Diaz Reports Financial & Operating Results for First Nine Months of 2006 — Market Wire - Energy and Utilities
- Idera Pharmaceuticals Announces Financial Results for the 3 and 9 Months Ended 9/30/2006 — Operations-Related News from StratCenter.com
- Jaclyn Reports First Quarter Financial Results; Announces Developments Concerning Purchase Option on West New York Facility — ArriveNet : Press Releases
- Excel Maritime: Excel Maritime Reports Results for the Third Quarter and Nine Month Period Ended September 30, 2006 — Market Wire - Earnings Reports
- Silverstar Holdings: Silverstar Holdings Announces Financial Results for Period Ending September 30, 2006 — Market Wire - Lifestyle and Leisure
- Miramar Mining Reports Financial Results for Third Quarter 2006 — ArriveNet : Business
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech